Skip to Content

Join the 'Defitelio' group to help and get support from people like you.

Defitelio News

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation

Posted 31 Mar 2016 by Drugs.com

March 30, 2016 – The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition. HSCT is a procedure performed in some patients to treat certain blood or bone marrow cancers. Immediately before an HSCT procedure, a patient receives chemotherapy. Hepatic VOD can occur in patients who receive chemotherapy and HSCT. Hepatic VOD is a condition in which some of the veins in the liver become blocked, causing swelling and a decrease in blood flow inside the liver, which may lead to liver damage. In the most ... Read more

Related support groups: Thrombotic/Thromboembolic Disorder, Defibrotide, Defitelio

Ask a Question

Further Information

Related Condition Support Groups

Hepatic veno-occlusive disease

Defitelio Patient Information at Drugs.com